The development of treatments for dementia is advancing with steady steps, and early diagnosis is considered critical. Biomarkers are central components of drug development in Alzheimer's disease and related disorders including dementia with lewy bodies, frontotemporal dementia, and vascular dementia, and so forth. Therefore, we would like to focus upon biomarkers as the theme.

We invite authors to submit original research and review articles about biomarkers for Alzheimer's disease and related disorders including dementia with lewy bodies, frontotemporal dementia, and vascular dementia in basic and clinical research. Potential topics include, but are not limited to:

• Recent developments of genetic testing
• Advances of structural imaging (CT, MRI, etc.)
• Advances of functional imaging (SPECT, PET, Amyloid imaging, etc.)
• Recent developments of peripheral markers (cerebrospinal fluid, serum, fibroblast, etc.)
• Role of new biomarkers for disease modifying therapies

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ijad/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: